Suppr超能文献

一种可消融难治性、低生长分数肿瘤的抗癌治疗方法的临床前及临床验证

PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS.

作者信息

Sorscher Eric J, Hong Jeong S, Parker William B

机构信息

atlanta, georgia.

出版信息

Trans Am Clin Climatol Assoc. 2016;127:59-70.

Abstract

Intratumoral expression of the purine nucleoside phosphorylase (PNP) gene was originally described by our laboratories as a means to inhibit growth of solid tumors . The approach generates purine bases that disrupt DNA, RNA, and protein synthesis, a unique mechanism when compared with all approved or experimental cancer therapeutics. Use of PNP has been validated by numerous laboratories worldwide against human tumor xenografts (lung, liver, pancreas, bladder, glioma, and prostate, among others). Data from a recently completed phase 1 clinical trial has indicated substantial anti-cancer activity in human subjects with no serious toxicities.

摘要

我们实验室最初描述了嘌呤核苷磷酸化酶(PNP)基因在肿瘤内的表达,这是一种抑制实体瘤生长的方法。该方法产生的嘌呤碱会破坏DNA、RNA和蛋白质合成,与所有已批准或实验性癌症治疗方法相比,这是一种独特的机制。全球众多实验室已针对人肿瘤异种移植(包括肺癌、肝癌、胰腺癌、膀胱癌、神经胶质瘤和前列腺癌等)验证了PNP的用途。最近完成的一项1期临床试验的数据表明,该药物在人类受试者中具有显著的抗癌活性,且无严重毒性。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验